top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Funding Activity May 13th-17th 2024

New antibody company launched and more funding events…

Want to get this list of recently funded companies and more data? Fill out a quote request to get more info or set up a call (Quote Request Form)

FIG. 1. Recent Biotech Funding Activity.

Private Funding –

Celaid Therapeutics

💸  Completed series A funding worth a total of 1.2B yen

Uniquity Bio

💸  Launched with $300M capital from Blackstone Life Sciences to Start Phase 2 Clinical Trials in COPD & Asthma with Novel Anti-TSLP Monoclonal Antibody

Lycia Therapeutics

💸  Completed $106.6M series C funding to advance LYTAC extracellular protein degraders pipeline. 

Attovia Therapeutics 

💸  Raised $105m in Series B financing led by Goldman Sachs Alternatives to advance its lead programs and expand pipeline

CinDome Pharma

💸  Announced $40M Series B financing extension to support Deudomperidone Ph 2 envision3D trial. 

Post-IPO/Public Funding –


🏦  Announced pricing for $160M equity offering with J.P. Morgan and BofA Securities as joint book-running managers.

Cassava Sciences

🏦  Raised $125M from equity financing through exercised warrants to fund simufilam development.


🏦  Raised $115M in an oversubscribed public offering. 

ADC Therapeutics

🏦  Announced $105M offering and pre-funded warrants.

Reneo Pharmaceuticals

🏦  Proposed merger w/ OnKure which includes $65M private investment in public equity (PIPE) financing. 


Article History:

RF, DV, DG (05/21/24)

This article is not investment or legal advice.


bottom of page